previously several years, the UK has witnessed a revolution in health-related bodyweight‑reduction treatment plans — from the introduction of semaglutide (Wegovy®) towards the expanding reputation of tirzepatide (Mounjaro®). Now, An additional name is drawing interest in the two clinical and comm